SutroVax, a recently established biopharmaceutical vaccine company, today announced the completion of a $22 million Series A financing. SutroVax is developing vaccines for infectious disease targets, with an initial emphasis on best-in-class conjugate vaccines, using an exclusive license to Sutro Biopharma’s Xpress CF and Xpress CF+ platforms for cell free protein synthesis and site-specific conjugation respectively.

View the original here:
SutroVax completes $22 million Series A financing

Scroll to Top